TSX Exchange Symbol: RVX
ORLANDO, FL, Nov. 5 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral Administration of Compound RVX-208 Increases Serum Levels of ApoA-I and Improves High-Density Lipoprotein-Mediated Cholesterol Efflux in African Green Monkeys" was presented by Dr. Jacques Genest.
Dr. Jacques Genest, MD, Director of the Division of Cardiology at McGill University Health Centre/Royal Victoria Hospital said, "We were excited about this data and felt that it should be presented at this prestigious conference. Resverlogix's novel drug demonstrated the ability to increase the production of ApoA-I and functional HDL. Notably we saw increases in pre beta HDL sub particles, which improve HDL's ability to mediate cholesterol efflux."
"We are very pleased to have our data presented at one of the most prestigious conferences for cardiovascular disease," stated Dr. Jan Johansson, MD, Ph.D., Senior Vice President, Clinical Affairs of Resverlogix. "Our small molecule, RVX-208, by virtue of increasing endogenous production of ApoA-I and functional HDL has huge potential to address the unmet medical need of cardiovascular disease," added Dr Johansson.
Apolipoprotein A-I (ApoA-I), the main component of high-density
lipoprotein (HDL) represent the bodies natural defense system against
atherosclerosis by mediating reverse cholesterol transport, i.e. transport
of peripheral cholesterol including that of the vessel wall to the liver
for processing. In multiple human and animal studies over-expression or
repeated infusion of ApoA-I inhibit progression and induce regression of
atherosclerosis in animals and humans. In his presentation Dr. Genest
discussed the effects of oral administration of RV
|SOURCE Resverlogix Corp.|
Copyright©2007 PR Newswire.
All rights reserved